RQ-02

RQ-02 is a preclinical-stage stapled lipopeptide antiviral candidate being developed by Red Queen Therapeutics. It is designed as a broad-spectrum therapeutic to target multiple respiratory viruses, including respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza viruses (PIV-1, PIV-2, PIV-3, and PIV-4). The drug utilizes a novel modality that combines peptide-based targeting with chemical stapling and lipid modifications to enhance stability and mucosal persistence. Its mechanism of action involves binding to highly conserved heptad repeat domains of viral fusion proteins, thereby blocking the six-helix bundle assembly required for the virus to fuse with host cell membranes. By preventing viral entry, RQ-02 aims to provide a potent intervention against a range of respiratory pathogens across different viral families.